CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence study

Jae Yong Chung, Yoon Jung Lee, Seong Bok Jang, Lay Ahyoung Lim, Min Soo Park, Kyunghwan Kim

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Tacrolimus is metabolized by CYP3A and has highly variable pharmacokinetics. To study the factors contributing to this high variability in pharmacokinetics and to investigate the possibility of genotype-specific clinical applications, the effect of differing CYP3A5 genotypes on the intrasubject coefficients of variation for tacrolimus was investigated. Genotyping for CYP3A5*3 was performed in healthy volunteers who had previously participated in the pharmacokinetic study of 2 tacrolimus formulations with a 2 × 2 cross-over design. Intrasubject coefficients of variation calculated from analysis of variation in CYP3A5*1/*1+ *1/*3 (n = 16) and CYP3A5*3/*3 (n = 13) groups were compared. The intrasubject CVs of AUC last and C max in the CYP3A5*3/*3 group were about 41.1% and 52.4% greater than those in the CYP3A5*1*1+*1/*3 group. The estimated total sample size for the bioequivalence study of tacrolimus with a 2 × 2 cross-over design was increased by 93.3% for AUC last (n = 30 versus 58) and 121.4% for C max (n = 28 versus 62) in the CYP3A5*3/*3 group compared with the CYP3A5*1/*1+*1/*3 group. The intraindividual variability of tacrolimus PK parameters may be associated with the CYP3A5 genotype. We propose that genotyping for CYP3A5 will provide a more efficient approach for bioequivalence designs and therapeutic drug monitoring.

Original languageEnglish
Pages (from-to)67-72
Number of pages6
JournalTherapeutic Drug Monitoring
Volume32
Issue number1
DOIs
Publication statusPublished - 2010 Feb 1

Fingerprint

Cytochrome P-450 CYP3A
Therapeutic Equivalency
Tacrolimus
Pharmacokinetics
Genotype
Cross-Over Studies
Area Under Curve
Drug Monitoring
Sample Size
Healthy Volunteers

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Yong Chung, Jae ; Jung Lee, Yoon ; Bok Jang, Seong ; Ahyoung Lim, Lay ; Soo Park, Min ; Kim, Kyunghwan. / CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence study. In: Therapeutic Drug Monitoring. 2010 ; Vol. 32, No. 1. pp. 67-72.
@article{074b8be881b44745a0d81acada8227b6,
title = "CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence study",
abstract = "Tacrolimus is metabolized by CYP3A and has highly variable pharmacokinetics. To study the factors contributing to this high variability in pharmacokinetics and to investigate the possibility of genotype-specific clinical applications, the effect of differing CYP3A5 genotypes on the intrasubject coefficients of variation for tacrolimus was investigated. Genotyping for CYP3A5*3 was performed in healthy volunteers who had previously participated in the pharmacokinetic study of 2 tacrolimus formulations with a 2 × 2 cross-over design. Intrasubject coefficients of variation calculated from analysis of variation in CYP3A5*1/*1+ *1/*3 (n = 16) and CYP3A5*3/*3 (n = 13) groups were compared. The intrasubject CVs of AUC last and C max in the CYP3A5*3/*3 group were about 41.1{\%} and 52.4{\%} greater than those in the CYP3A5*1*1+*1/*3 group. The estimated total sample size for the bioequivalence study of tacrolimus with a 2 × 2 cross-over design was increased by 93.3{\%} for AUC last (n = 30 versus 58) and 121.4{\%} for C max (n = 28 versus 62) in the CYP3A5*3/*3 group compared with the CYP3A5*1/*1+*1/*3 group. The intraindividual variability of tacrolimus PK parameters may be associated with the CYP3A5 genotype. We propose that genotyping for CYP3A5 will provide a more efficient approach for bioequivalence designs and therapeutic drug monitoring.",
author = "{Yong Chung}, Jae and {Jung Lee}, Yoon and {Bok Jang}, Seong and {Ahyoung Lim}, Lay and {Soo Park}, Min and Kyunghwan Kim",
year = "2010",
month = "2",
day = "1",
doi = "10.1097/FTD.0b013e3181c49a4c",
language = "English",
volume = "32",
pages = "67--72",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence study. / Yong Chung, Jae; Jung Lee, Yoon; Bok Jang, Seong; Ahyoung Lim, Lay; Soo Park, Min; Kim, Kyunghwan.

In: Therapeutic Drug Monitoring, Vol. 32, No. 1, 01.02.2010, p. 67-72.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence study

AU - Yong Chung, Jae

AU - Jung Lee, Yoon

AU - Bok Jang, Seong

AU - Ahyoung Lim, Lay

AU - Soo Park, Min

AU - Kim, Kyunghwan

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Tacrolimus is metabolized by CYP3A and has highly variable pharmacokinetics. To study the factors contributing to this high variability in pharmacokinetics and to investigate the possibility of genotype-specific clinical applications, the effect of differing CYP3A5 genotypes on the intrasubject coefficients of variation for tacrolimus was investigated. Genotyping for CYP3A5*3 was performed in healthy volunteers who had previously participated in the pharmacokinetic study of 2 tacrolimus formulations with a 2 × 2 cross-over design. Intrasubject coefficients of variation calculated from analysis of variation in CYP3A5*1/*1+ *1/*3 (n = 16) and CYP3A5*3/*3 (n = 13) groups were compared. The intrasubject CVs of AUC last and C max in the CYP3A5*3/*3 group were about 41.1% and 52.4% greater than those in the CYP3A5*1*1+*1/*3 group. The estimated total sample size for the bioequivalence study of tacrolimus with a 2 × 2 cross-over design was increased by 93.3% for AUC last (n = 30 versus 58) and 121.4% for C max (n = 28 versus 62) in the CYP3A5*3/*3 group compared with the CYP3A5*1/*1+*1/*3 group. The intraindividual variability of tacrolimus PK parameters may be associated with the CYP3A5 genotype. We propose that genotyping for CYP3A5 will provide a more efficient approach for bioequivalence designs and therapeutic drug monitoring.

AB - Tacrolimus is metabolized by CYP3A and has highly variable pharmacokinetics. To study the factors contributing to this high variability in pharmacokinetics and to investigate the possibility of genotype-specific clinical applications, the effect of differing CYP3A5 genotypes on the intrasubject coefficients of variation for tacrolimus was investigated. Genotyping for CYP3A5*3 was performed in healthy volunteers who had previously participated in the pharmacokinetic study of 2 tacrolimus formulations with a 2 × 2 cross-over design. Intrasubject coefficients of variation calculated from analysis of variation in CYP3A5*1/*1+ *1/*3 (n = 16) and CYP3A5*3/*3 (n = 13) groups were compared. The intrasubject CVs of AUC last and C max in the CYP3A5*3/*3 group were about 41.1% and 52.4% greater than those in the CYP3A5*1*1+*1/*3 group. The estimated total sample size for the bioequivalence study of tacrolimus with a 2 × 2 cross-over design was increased by 93.3% for AUC last (n = 30 versus 58) and 121.4% for C max (n = 28 versus 62) in the CYP3A5*3/*3 group compared with the CYP3A5*1/*1+*1/*3 group. The intraindividual variability of tacrolimus PK parameters may be associated with the CYP3A5 genotype. We propose that genotyping for CYP3A5 will provide a more efficient approach for bioequivalence designs and therapeutic drug monitoring.

UR - http://www.scopus.com/inward/record.url?scp=75749114491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749114491&partnerID=8YFLogxK

U2 - 10.1097/FTD.0b013e3181c49a4c

DO - 10.1097/FTD.0b013e3181c49a4c

M3 - Article

VL - 32

SP - 67

EP - 72

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 1

ER -